Sutro Biopharma Secures $110M Public Offering, Extends Cash Runway into Q2 2028

summarizeSummary

Sutro Biopharma finalized a public offering of 7.87 million shares at $13.98 each, raising $110 million gross and extending its cash runway into Q2 2028, a highly dilutive but crucial financing event.

check_boxKey Events · Financing and Capital Events · STRO

• Public Offering Finalized

  The company entered an underwriting agreement to sell 7,868,383 common shares at an offering price of $13.98 per share, formalizing the terms of the offering initiated on 2026-02-10.

• Significant Capital Raise

  The offering is expected to generate approximately $110.0 million in gross proceeds, providing critical funding for the company's operations.

• Extended Cash Runway

  Combined with existing cash, the proceeds are projected to fund operating expenses and capital expenditures into the second quarter of 2028.

• Dilutive Transaction

  The offering represents a substantial dilution to existing shareholders, with the offering price at a discount to the current market price of $15.03.

auto_awesomeAnalysis · STRO · Life Sciences

Sutro Biopharma entered into an underwriting agreement for a public offering of 7.87 million common shares at $13.98 per share, aiming to raise approximately $110.0 million in gross proceeds. This substantial capital raise, while highly dilutive, is critical for extending its financial runway. The company projects these funds, combined with existing cash, will be sufficient to cover operating expenses and capital expenditures into the second quarter of 2028. This financing provides essential liquidity for the life sciences company to continue its research, clinical development, and manufacturing of product candidates.